Canadian Free Press Release & Media Distribution Service


Wire Service Media wants to thank all of our users and partners over our long run started back in 2007, but it's time for the owner to move on.

The sale includes the website, domain name, user base and related social media channels were applicable. Please express your interest to -

Thank you for your understanding and patronage.


Press Release | Business

Press Release: ImmunoCellular Therapeutics (IMUC) Edges Higher

Bookmark and Share


On February 14th, ImmunoCellular Therapeutics' (IMUC) CEO, Manish Singh, Ph.D., is scheduled to present at the 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference should attract institutional investment, as fund managers learn of the cancer therapeutics ImmunoCellular (IMUC) is developing.

As noted (see my article here), ImmunoCellular's lead product candidate, ICT-107, returned stellar results from Phase 1 clinical trials in the treatment of brain tumors.

Above-average share volume has been seen for at least 8-consecutive trading sessions, coincidentally since we began coverage of ImmunoCellular Therapeutics (IMUC). During this period, the stock price has gained $0.50 or 28%, encroaching on a new 52-week high. While drivers such as clinical trial results, product and corporate developments remain fundamental, relative price movement will be the catalyst to market momentum for this small biotechnology firm.

As I explain in the following video, relative price movement is an analysis of the price at a specific point in time, better known as technical analysis. Using IMUC's chart, I interpret the relative price at this point in time, the key technical drivers moving forward, and what the technical indicators are telling us. 

Click on the link to view my analysis.
Regarding the company's presentation at the 13th Annual BIO CEO & Investor Conference, a webcast of the event will be available at
Please note well:
The employees of are not Registered as Investment Advisors in any jurisdiction whatsoever. Full disclaimer can be read
here.  We have previously been compensated for voicing an independent investment opinion of ImmunoCellular Therapeutics, Ltd. The views expressed are purely our own and do not constitute a buy or sell recommendation

Add a new Comment

Follow Us